Harvest Fund Management Co. Ltd Buys 1,366 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Harvest Fund Management Co. Ltd grew its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 27.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,360 shares of the biopharmaceutical company's stock after purchasing an additional 1,366 shares during the quarter. Harvest Fund Management Co. Ltd's holdings in Regeneron Pharmaceuticals were worth $4,388,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. FSA Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $28,000. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares in the last quarter. Avalon Trust Co bought a new position in Regeneron Pharmaceuticals during the fourth quarter worth $36,000. Finally, Private Wealth Management Group LLC boosted its holdings in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Down 0.6 %

REGN stock traded down $4.14 during midday trading on Friday, reaching $658.48. The company had a trading volume of 1,869,108 shares, compared to its average volume of 634,475. The company has a 50 day moving average of $689.43 and a two-hundred day moving average of $815.71. The company has a market capitalization of $71.99 billion, a P/E ratio of 17.20, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the company earned $11.86 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.53%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on REGN shares. Citigroup dropped their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. TD Cowen decreased their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research report on Tuesday, February 4th. Bernstein Bank dropped their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. UBS Group cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.